APOE Alzheimer's Risk
Use
This test is to detect the presence of the APOE4 variant, which is associated with increased risk of late-onset (age >60-65) Alzheimer's disease (AD). Testing may be considered for patients with dementia to supplement information from clinical and other evaluations. This test is not appropriate for children. APOE genotype results are E2/E2, E2/E3, E2/E4, E3/E3, E3,E4, or E4/E4. APOE genotyping supplies supplementary information for the clinical diagnosis of Alzheimer's disease.
Special Instructions
Not provided.
Limitations
APOE genotype indicates risk but is not diagnostic; presence of E4 allele(s) increases risk but does not mean disease will develop. Clinical interpretation should include other factors. Risk assessment is limited to Alzheimer’s-related susceptibility and ARIA risk; not appropriate for diagnostic use in asymptomatic individuals or children.
Methodology
PCR-based (PCR)
Biomarkers
APOE
Gene
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
Not provided
Container
Lavender‑top (EDTA) tube or yellow‑top (ACD) tube
Storage Instructions
Room temperature
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 28 days |
| Refrigerated | 28 days |
Other tests from different labs that may be relevant